Trial of Psilocybin versus Escitalopram for Depression
2021 · New England Journal of Medicine · 1,297 citations
https://doi.org/10.1056/nejmoa2032994
D
David Erritzøe
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
243
Papers
15.7K
Citations
55
h-index
126
i10-index
David Erritzøe is an academic researcher from Imperial College London. The author has contributed to research in topics: Psychedelics and Drug Studies & Neurotransmitter Receptor Influence on Behavior & Chemical synthesis and alkaloids. The author has an h-index of 55, co-authored 207 publications.
ORCID: 0000-0002-7022-6211Papers by this author
worksPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
2017 · Psychopharmacology · 935 citations
https://doi.org/10.1007/s00213-017-4771-x
Increased global integration in the brain after psilocybin therapy for depression
2022 · Nature Medicine · 417 citations
https://doi.org/10.1038/s41591-022-01744-z
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
2020 · Acta Psychiatrica Scandinavica · 334 citations
https://doi.org/10.1111/acps.13249
Neural substrates of cue reactivity and craving in gambling disorder
2017 · Translational Psychiatry · 176 citations
https://doi.org/10.1038/tp.2016.256
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
2021 · Scientific Reports · 150 citations
https://doi.org/10.1038/s41598-021-81446-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat